Cybin Corp. Archives - QualityStocks

FridayNov 06, 2020 11:16 am

QualityStocksNewsBreaks – CYBIN Inc. Completes Reverse Takeover Transaction

CYBIN (formerly Clarmin Explorations Inc.), a life sciences company initially focused on psychedelic pharmaceutical therapies, on Thursday announced it has completed its previously disclosed reverse takeover of Clarmin Explorations Inc. per the terms of an amalgamation agreement dated June 26, 2020, as amended on October 21, 2020. The agreement was among Cybin Corp., Clarmin and 2762898 Ontario Inc. (“SubCo”), a wholly-owned subsidiary of the company (the “reverse takeover”), in which the reverse takeover was completed by way of a “three-cornered” amalgamation pursuant to the provisions of the Business Corporations Act (Ontario). Through the reverse takeover, Cybin Corp. amalgamated with SubCo…

MondayNov 02, 2020 2:41 pm

QualityStocksNewsBreaks – Cybin Corp. Paves Path to Profitability with Health-Care Veteran at the Helm

Cybin Corp., a Canada-based, life-science company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://ibn.fm/UTTdr). Drysdale, named an Ernst and Young Entrepreneur of the Year in 2012, brings more than three decades of experience in the health-care sector and will continue to grow the company’s IP portfolio. “With his myriad of business accomplishments, Doug is the ideal leader for Cybin,” stated Cybin co-founder and COO Paul Glavine of the appointment. “We believe that his extensive health-care sector background and international company management skills will help Cybin strengthen partnerships, develop strategic alliances and expand our international…

MondayNov 02, 2020 12:32 pm

CYBIN Corp. Set to Benefit from Growing Research, Interest in Psychedelics

Backed by an anonymous donor, Berkeley launches a center for psychedelic science and public education Berkley follows examples of other notable universities such as Johns Hopkins in Maryland, Imperial College in London, and Canadian Centre for Psychedelic Science As an innovative company focusing on psilocybin, CYBIN is set to capitalize on growing academic, commercial attention UC Berkeley is joining other prominent academic institutions, including Johns Hopkins University in Maryland and Imperial College in London, to accelerate the scientific research of psilocybin by launching a new center focusing on the compound (https://ibn.fm/CL4wX). As a mushroom life science company that expects to…

ThursdayOct 22, 2020 9:57 am

Cybin Corp. Appoints New CEO with Impressive Health-Care Expertise

Cybin appoints health-care expert Doug Drysdale as new CEO. Company confident that his extensive health-care sector background, international company management skills will strengthen Cybin partnerships. New CEO says business model, talented management team positions company to examine new psychedelic-based therapies, delivery systems. Cybin Corp.,a life sciences company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://ibn.fm/vOTXM). Drysdale brings more than three decades of experience in the health-care sector and will continue to grow its IP portfolio. “With his myriad business accomplishments, Doug is the ideal leader for Cybin,” said Cybin co-founder and COO Paul Glavine. “We…

MondayOct 12, 2020 2:48 pm

QualityStocksNewsBreaks – Cybin Corp. Holds Distinct Strength in Psychedelics Space

Cybin Corp., a Canada-based, life-science company, is focused on the development of mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products. The company is positioning as countries around the world become increasingly accepting of psilocybin’s use in controlled settings and recent clinical studies unveil its potential in treating mental health disorders and other conditions. A recent article discussing the company’s pioneering efforts on this front reads, “Cybin already holds a unique strength in the psychedelics space. The company is responsible for some of the first published research on microdosing; i.e, the action or practice of taking or administering very small amounts of…

FridayOct 02, 2020 1:28 pm

QualityStocksNewsBreaks – Cybin Corp. CEO Eyes Opportunity in Psychedelics Space, Organic IP Expansion

Cybin Corp., a Canada-based, life-science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, recently announced the appointment of Doug Drysdale as the company’s chief executive officer. Well recognized in the pharmaceutical space, Drysdale brings more than three decades of experience and a recognition of psychedelics as a major breakthrough in treating mental health conditions. Amid the recent strong push for research and commercialization in the psychedelics sector, Drysdale seeks to pursue emerging opportunities and pave the road for the company’s rapid growth. “I am beyond excited to be joining the Cybin team,” Drysdale stated in a recent article of…

FridaySep 25, 2020 2:07 pm

QualityStocksNewsBreaks – Cybin Corp. Leverages Two-Pronged Approach to Target Psychedelic, Nutraceutical Sectors

Cybin Corp., a Canada-based life-science company, looks to benefit from its growing footprint in two billion-dollar markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see significant growth in the coming years. The global nutraceutical market was valued at $382.51 billion in 2019 and is expected to grow at an 8.3% compound annual growth rate (“CAGR”) over the next seven years. Meanwhile, the psychedelic drugs market is projected to reach $6.85 billion by 2027. Cybin’s business model is structured around two wholly owned divisions focused on targeting both promising spaces. A recent article discussing this reads, “Cybin is committed…

WednesdaySep 23, 2020 1:51 pm

United Bid to Liberalize Use of Psilocybin Strengthens

Leading UK scientists, policy group call for rescheduling of psilocybin amid looming mental health crisis Sent to the Home Office with statements of support from leading scientists, paper urges for psilocybin use on a research-only model Cybin Corp. to capitalize on international expansion of psilocybin use as a company active in both research, nonclinical spaces The United Kingdom (“UK”) is joining other countries, including Canada, in a push to facilitate the wider use of psilocybin, a naturally occurring compound found in mushrooms. Focusing on psychedelic and nutraceutical products, Cybin Corp. is poised to leverage the growing global momentum the compound is…

FridaySep 18, 2020 12:52 pm

Cybin Corp. New CEO Set to Pave Path to Profitability, Grow IP Portfolio Organically

Cybin announces appointment of established pharma industry figure as new CEO Drysdale leverages 30 years of leadership, entrepreneurial experience in life-science space Announcement comes as Cybin sets out on path to profitability Cybin Corp., an innovative life science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, has announced the appointment of Mr. Doug Drysdale as the company’s Chief Executive Officer. With more than three decades of experience, the new leader recognizes psychedelics as a major breakthrough in treating mental health conditions. Drysdale joins Cybin to pave the road for the company’s rapid growth, underpinned by the recent strong push…

WednesdaySep 16, 2020 3:02 pm

Cybin Corp. Leads Out in Growing Billion-Dollar Nutraceutical, Psychedelic Markets

Global nutraceutical market valued at $ 382.51 billion; psychedelic drugs market to reach $6.85 billion Cybin deploys two-pronged approach covering both psychedelic pharmaceutical and nutraceutical segments As psilocybin continues to prove effective in treating mental health conditions, the company is poised to leverage vast addressable market Cybin Corp., a Canadian early-stage life sciences company appears ideally positioned in two promising markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see impressive growth in the coming years. Cybin looks to benefit from its growing footprint in both spaces. In 2019, the global nutraceutical market was valued at $382.51 billion. The…

Site Search

Company Search

Tag: Cybin Corp.